From USFDA
Zydus Cadila has received the final approval from the USFDA to market Candesartan Cilexetil and Hydrochlorothiazide Tablets USP in the strength of 16 mg /12 mg, 32 mg/12.5 mg and 32 mg/ 25 mg.The drug combines an angiotensin II receptor (type ATI) antagonist and a diuretic, hydrochlorothiazide and is used to treat high blood pressure.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
